Edgestream Partners L.P. boosted its position in Balchem Co. (NASDAQ:BCPC - Free Report) by 403.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 45,815 shares of the basic materials company's stock after acquiring an additional 36,706 shares during the quarter. Edgestream Partners L.P. owned 0.14% of Balchem worth $7,468,000 at the end of the most recent reporting period.
Other hedge funds have also added to or reduced their stakes in the company. Watts Gwilliam & Co. LLC increased its stake in Balchem by 63.7% in the fourth quarter. Watts Gwilliam & Co. LLC now owns 35,069 shares of the basic materials company's stock valued at $5,438,000 after acquiring an additional 13,642 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Balchem by 1.7% during the third quarter. JPMorgan Chase & Co. now owns 458,986 shares of the basic materials company's stock worth $80,782,000 after buying an additional 7,721 shares during the last quarter. Stifel Financial Corp grew its stake in shares of Balchem by 26.2% during the third quarter. Stifel Financial Corp now owns 11,893 shares of the basic materials company's stock worth $2,093,000 after buying an additional 2,467 shares during the last quarter. Apollon Wealth Management LLC bought a new stake in shares of Balchem during the fourth quarter worth $503,000. Finally, Congress Asset Management Co. grew its stake in shares of Balchem by 5.4% during the fourth quarter. Congress Asset Management Co. now owns 317,610 shares of the basic materials company's stock worth $51,769,000 after buying an additional 16,170 shares during the last quarter. 87.91% of the stock is owned by institutional investors.
Analyst Ratings Changes
BCPC has been the topic of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $190.00 target price on shares of Balchem in a research note on Monday, February 24th. StockNews.com cut shares of Balchem from a "buy" rating to a "hold" rating in a research note on Tuesday, February 25th. Finally, Sidoti raised shares of Balchem to a "hold" rating in a research note on Tuesday, February 25th.
Check Out Our Latest Stock Analysis on BCPC
Balchem Trading Down 0.3 %
Shares of NASDAQ:BCPC traded down $0.47 during mid-day trading on Friday, reaching $175.69. 179,690 shares of the company's stock were exchanged, compared to its average volume of 135,834. The firm has a market capitalization of $5.72 billion, a price-to-earnings ratio of 44.70, a PEG ratio of 4.41 and a beta of 0.63. The business's fifty day moving average price is $163.17 and its 200-day moving average price is $169.84. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.16 and a current ratio of 1.99. Balchem Co. has a twelve month low of $137.69 and a twelve month high of $186.03.
Balchem (NASDAQ:BCPC - Get Free Report) last issued its quarterly earnings results on Friday, February 21st. The basic materials company reported $1.03 EPS for the quarter, missing analysts' consensus estimates of $1.11 by ($0.08). The business had revenue of $240.00 million for the quarter, compared to analyst estimates of $239.96 million. Balchem had a return on equity of 11.37% and a net margin of 13.47%. On average, research analysts predict that Balchem Co. will post 4.64 EPS for the current fiscal year.
Balchem Increases Dividend
The firm also recently declared an annual dividend, which was paid on Friday, January 17th. Stockholders of record on Thursday, December 26th were issued a dividend of $0.87 per share. This represents a dividend yield of 0.4%. The ex-dividend date was Thursday, December 26th. This is a positive change from Balchem's previous annual dividend of $0.79. Balchem's payout ratio is 22.14%.
Balchem Profile
(
Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Featured Stories
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
